AGIBOT Nears RMB 50B Valuation as Humanoid Delivery Begins
AGIBOT is closing a RMB 1 to 1.5 billion round at a roughly RMB 50 billion valuation, the highest yet recorded for a Chinese humanoid startup, with the transaction potentially pushing its Hong Kong listing past year end. That figure sets a new capital-markets reference point for the sector.
Delivery volumes are becoming the operative metric. UBTECH's U1 full-size bionic humanoid entered small-batch delivery more than 100 days after launch, and the company confirmed a youth edition for the fourth quarter. At the 26th China International Industry Fair, exhibitors shifted floor space from staged performances toward actual manufacturing tasks, a reallocation indicating buyers are testing throughput rather than spectacle.
Manufacturing depth remains concentrated. Boston Dynamics disclosed that Atlas components are machined in-house, with assembly and repair handled through rapid build cycles and real-time shop-floor collaboration. Few humanoid programmes publish such process detail, and the disclosure suggests the gap between prototype iteration and repeatable production is still the binding constraint.
On technical architecture, LimX Dynamics argued that vision cannot function as an isolated module and must be coupled with decision-making, locomotion and manipulation within one system. ABB Robotics' China president said SoftBank's acquisition of the unit is proceeding on schedule, and Shanghai's party secretary met Bosch's chief executive to discuss robotics and industrial upgrading, indicating foreign asset reshuffling continues alongside local policy support.
Two observations follow. First, valuation and delivery now move on separate clocks: capital is pricing a platform, while shipped units remain counted in small batches. Second, field deployment is broadening beyond factories, as DEEP Robotics' M20S quadruped conducted off-road survey work in the Ailao Mountains, hauling equipment and supporting wildlife observation. Whether fourth-quarter youth editions and IPO timelines validate the current valuation is the point to watch.